/
/
/

Concord Biotech Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022
₹257 Cr₹326 Cr₹278 Cr₹247 Cr₹204 Cr₹430 Cr₹244 Cr₹310 Cr₹216 Cr₹319 Cr₹241 Cr₹262 Cr₹195 Cr₹273 Cr₹241 Cr₹159 Cr₹181 Cr
₹13 Cr₹15 Cr₹10 Cr₹13 Cr₹14 Cr₹9 Cr₹15 Cr₹10 Cr₹10 Cr₹11 Cr₹8 Cr₹8 Cr₹7 Cr₹12 Cr₹9 Cr₹6 Cr₹8 Cr
₹270 Cr₹341 Cr₹288 Cr₹260 Cr₹218 Cr₹439 Cr₹259 Cr₹320 Cr₹226 Cr₹330 Cr₹249 Cr₹270 Cr₹201 Cr₹285 Cr₹250 Cr₹165 Cr₹189 Cr
₹193 Cr₹227 Cr₹198 Cr₹177 Cr₹160 Cr₹254 Cr₹160 Cr₹187 Cr₹148 Cr₹198 Cr₹148 Cr₹156 Cr₹136 Cr₹158 Cr₹143 Cr₹133 Cr₹130 Cr
₹95 Cr₹134 Cr₹109 Cr₹102 Cr₹75 Cr₹200 Cr₹113 Cr₹147 Cr₹92 Cr₹145 Cr₹114 Cr₹127 Cr₹79 Cr₹141 Cr₹121 Cr₹44 Cr₹72 Cr
₹4 L₹8 L₹8 L₹6 L₹6 L₹10 L₹10 L₹10 L₹24 L₹46 L₹50 L₹84 L₹75 L₹1 Cr₹91 L₹1 Cr₹1 Cr
₹77 Cr₹114 Cr₹87 Cr₹83 Cr₹57 Cr₹185 Cr₹99 Cr₹133 Cr₹78 Cr₹131 Cr₹100 Cr₹113 Cr₹65 Cr₹126 Cr₹106 Cr₹30 Cr₹58 Cr
₹56 Cr₹89 Cr₹64 Cr₹61 Cr₹43 Cr₹142 Cr₹74 Cr₹99 Cr₹58 Cr₹97 Cr₹75 Cr₹84 Cr₹48 Cr₹94 Cr₹79 Cr₹22 Cr₹43 Cr

Share Price Live Stats

Open (₹)1,450.00
Volume (₹)59,142.00
High (₹)1,450.40
Upper Circuit1,737.20
Low (₹)1,411.60
Lower Circuit1,158.20
Prev Close1,447.70
52W High (₹)1,730.00
Price1,417.10
52W Low (₹)987.00

Share Market Cap & Key Ratios Overview

M.Cap (₹)15153.10 Cr
Div. Yield (%)0.52
PE Ratio55.03
Debt to Equity0.00
Price to Book5.27
Book Value192.81
EPS (TTM)26.32
Face Value1.00
ROE (%)13.54

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
CONCORDBIONSE
LTP
1W Low
1W High
Market cap (₹)
1899-21 (-1.09%)
1895
1984.80
4,56,833Cr
9100-139 (-1.50%)
9087
9467
2,45,426Cr
4857-193 (-3.82%)
4823
5066
1,87,320Cr
1120-71 (-5.96%)
1120
1187
1,13,217Cr
1385-38.5 (-2.70%)
1375.50
1426.10
1,12,212Cr
1840-98.5 (-5.08%)
1811.70
1949
1,01,155Cr
2110-61.5 (-2.83%)
2100.60
2192
97,626Cr
2327.9-55 (-2.31%)
2317
2419.20
96,859Cr
1151-27 (-2.29%)
1151
1179.90
96,406Cr
1653.1+7.8 (0.47%)
1622.60
1717
93,614Cr
1417.1-64 (-4.32%)
1411.60
1504
15,153Cr

Key Highlights of Concord Biotech Ltd’s P&L

In 2026-03-31, Concord Biotech Ltd reported total revenue of ₹1107.25Cr, compared with ₹1244.54Cr in 2025-03-31, reflecting Concord Biotech Ltd turnover.

Depreciation was ₹74.46Cr and finance costs were ₹82.34Lakh in 2026-03-31

Profit Before Tax (PBT) has been ₹344.65Cr in 2026-03-31 as compared to ₹494.55Cr in 2025-03-31.

Net Profit (PAT) was ₹260.91Cr in 2026-03-31 compared with ₹371.64Cr in 2025-03-31.

Earnings per share (EPS) were ₹24.94 in 2026-03-31, compared with ₹35.52 in 2025-03-31.